| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 30.9MM | -32% |
| Operating Income | -18.3MM | -5% |
| Operating Expenses | 49.1MM | -24% |
| Net Income | -11.7MM | -28% |
| R&D | 36.6MM | -28% |
| G&A | 12.5MM | -7% |
| Amortization | 879K | +10% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider transaction.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider sale according to a recent SEC filing.
Arcturus Therapeutics Holdings ( NASDAQ:ARCT ) Full Year 2023 Results Key Financial Results Revenue: US$166.8m (down...
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds. If you want to skip our discussion on the biotech industry, head over to 5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds. Fitch Ratings maintains a Neutral outlook for the global pharmaceutical and biotech industry in […]
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript March 7, 2024 Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were $-1.69. ARCT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to […]
Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call
Revenue Declines Amidst Progress in mRNA Therapeutics and Extended Cash Runway
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 81.07% and 47.01%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Thursday reported a fourth-quarter loss of $8.6 million, after reporting a profit in the same period a year earlier. On a per-share basis, the San Diego-based company said it had a loss of 32 cents. The pharmaceutical company posted revenue of $34 million in the period, which fell short of Street forecasts.
SAN DIEGO, March 07, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2023, and provided corporate updates.